Q4 2024 13F Holders as of 12/31/2024
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
334M
-
Number of holders
-
294
-
Total 13F shares, excl. options
-
241M
-
Shares change
-
+4.8M
-
Total reported value, excl. options
-
$1.79B
-
Value change
-
+$28.5M
-
Put/Call ratio
-
1.45
-
Number of buys
-
134
-
Number of sells
-
-117
-
Price
-
$7.40
Significant Holders of IOVANCE BIOTHERAPEUTICS, INC. - Common Stock (IOVA) as of Q4 2024
354 filings reported holding IOVA - IOVANCE BIOTHERAPEUTICS, INC. - Common Stock as of Q4 2024.
IOVANCE BIOTHERAPEUTICS, INC. - Common Stock (IOVA) has 294 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 241M shares
of 334M outstanding shares and own 72.22% of the company stock.
Largest 10 shareholders include VANGUARD GROUP INC (27.5M shares), MHR FUND MANAGEMENT LLC (24.4M shares), BlackRock, Inc. (23.5M shares), PERCEPTIVE ADVISORS LLC (22.1M shares), STATE STREET CORP (12.2M shares), Hood River Capital Management LLC (8.99M shares), Soleus Capital Management, L.P. (6.56M shares), GEODE CAPITAL MANAGEMENT, LLC (5.87M shares), T. Rowe Price Investment Management, Inc. (5.83M shares), and Long Focus Capital Management, LLC (5.13M shares).
This table shows the top 294 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.